Michael J. Cross

Human pluripotent stem cells for modeling toxicity.

N. Hanley, M. Cross, N. Kitteringham, 2012, Advances in pharmacology.

CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program

Amy E. Chadwick, L. Djouhri, S. Webb, 2019, Monoclonal antibodies in immunodiagnosis and immunotherapy.

Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms

Paul Walker, Chris S. Pridgeon, Constanze Schlott, 2018, Archives of Toxicology.

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

W Suter, M Pirmohamed, M. Pirmohamed, 2011, British journal of pharmacology.

Safety pharmacology--current and emerging concepts.

Dominic P. Williams, J. Sidaway, S. Sethu, 2013, Toxicology and applied pharmacology.

Safety pharmacology — Current and emerging concepts D P R O O F

Dominic P. Williams, J. Sidaway, S. Sethu, 2013 .

Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist

Emma L. Smith, Dominic P. Williams, S. Webb, 2014, mAbs.